Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

OBJECTIVE: Foretinib (GSK1363089 or XL880), which is an oral multikinase inhibitor developed to primarily target the hepatocyte growth factor (HGF)/Met signaling pathway, has shown anti-tumor effects against some cancers in preclinical and clinical studies. RESULTS: HGF/Met signaling in endometrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogata, Yuhei, Tanaka, Tomohito, Ono, Yoshihiro J., Hayashi, Masami, Terai, Yoshito, Ohmichi, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978264/
https://www.ncbi.nlm.nih.gov/pubmed/29854314
http://dx.doi.org/10.18632/oncotarget.25232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978264/
https://www.ncbi.nlm.nih.gov/pubmed/29854314
http://dx.doi.org/10.18632/oncotarget.25232

Ejemplares similares